公开(公告)号：EP2968307A2

公开(公告)日：2016-01-20

申请号：EP14770495.1

申请日：2014-03-13

申请人： Purdue Pharma LP

发明人： YAO, Jiangchao ,  TAFESSE, Laykea

IPC分类号： A61K31/465 ,  A61K31/435 ,  C07D211/90 ,  A61P29/00 ,  A61P25/00

CPC分类号： C07D417/12 ,  C07D213/30 ,  C07D213/79 ,  C07D213/81 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/12

摘要： The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R
10 Z-HET-E I-A and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET, R
10 , and E are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I-A to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

摘要翻译： 本发明提供了取代的吡啶基，嘧啶基，吡嗪基，pyridazinyl-，和式IA的基于三嗪基甲酰胺：，R 10 Z-HET-E 1A和药学上可接受的盐和溶剂合物，其中Z，HET，R 10 和E的定义如说明书中所述。 本公开还涉及式I-A化合物用于治疗响应于钠通道阻断的病症的用途。 本公开的化合物对于治疗疼痛特别有用。

公开(公告)号：EP2240443B1

公开(公告)日：2013-11-20

申请号：EP09701185.2

申请日：2009-01-08

申请人： Purdue Pharma LP

发明人： SHAO, Bin ,  YAO, Jiangchao

IPC分类号： C07D207/48 ,  C07D409/12 ,  C07D409/14 ,  A61K31/381 ,  A61K31/401 ,  A61K31/4025 ,  A61P25/04

CPC分类号： C07D409/12 ,  C07D207/48 ,  C07D403/12 ,  C07D409/14

摘要： The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.

公开(公告)号：EP3101018B1

公开(公告)日：2019-03-06

申请号：EP16176601.9

申请日：2008-08-29

申请人： Purdue Pharma L.P. ,  SHIONOGI & CO., LTD.

发明人： GOEHRING, R. Richard ,  MATSUMURA, Akira ,  SHAO, Bin ,  TAODA, Yoshiyuki ,  TSUNO, Naoki ,  WHITEHEAD, John, W., F. ,  YAO, Jiangchao ,  FUCHINO, Kouki

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D451/04 ,  C07D451/14 ,  C07D471/14 ,  A61K31/498 ,  A61K31/4985 ,  A61P25/04

公开(公告)号：EP2164326A1

公开(公告)日：2010-03-24

申请号：EP08754805.3

申请日：2008-05-30

申请人： Euro-Celtique S.A. ,  Shionogi&Co., Ltd.

发明人： MATSUMURA, Akira ,  MIKAMIYAMA, Hidenori ,  YAO, Jiangchao

IPC分类号： A01N43/40 ,  A61K31/445

CPC分类号： C07D211/96 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The invention relates to amide compounds of Formula I: (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, etc.; R1 and R2 are each independently hydrogen, halogen, cyano, optionally substituted lower alky, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl etc. R3 and R4 are hydrogen, each optionally substituted lower alkyl, cycloalkyl, aryl or heterocyclyl etc.; X is ═O, optionally substituted lower alkyl, halogen, cyano, nitro etc., n is 0-5, m is 1 or 2 and p is 0-2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

公开(公告)号：EP3101018A1

公开(公告)日：2016-12-07

申请号：EP16176601.9

申请日：2008-08-29

申请人： Purdue Pharma L.P. ,  SHIONOGI & CO., LTD.

发明人： GOEHRING, R. Richard ,  MATSUMURA, Akira ,  SHAO, Bin ,  TAODA, Yoshiyuki ,  TSUNO, Naoki ,  WHITEHEAD, John, W., F. ,  YAO, Jiangchao ,  FUCHINO, Kouki

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D451/04 ,  C07D451/14 ,  C07D471/14 ,  A61K31/498 ,  A61K31/4985 ,  A61P25/04

CPC分类号： C07D451/14 ,  A61K31/498 ,  C07D401/04 ,  C07D401/14 ,  C07D451/04 ,  C07D471/08 ,  C07D471/14 ,  C07D487/04 ,  C07D498/08 ,  C07D519/00

摘要： The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds of formula (I) and formula (II), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

摘要翻译： 本发明涉及式（I）和式（II）的取代的喹喔啉型哌啶化合物，包含有效量的取代的喹喔啉型哌啶化合物的组合物和治疗或预防诸如疼痛的病症的方法，包括 向有需要的动物施用有效量的取代的喹喔啉型哌啶化合物。

公开(公告)号：EP2040698A2

公开(公告)日：2009-04-01

申请号：EP07810356.1

申请日：2007-07-12

申请人： SHIONOGI & CO., LTD. ,  Euro-Celtique S.A.

发明人： MATSUMURA, Akira ,  MIKAMIYAMA, Hidenori ,  TSUNO, Naoki ,  KYLE, Donald, J. ,  SHAO, Bin ,  YAO, Jiangchao

IPC分类号： A61K31/40 ,  C07D207/14

CPC分类号： C07D211/72 ,  C07D211/96 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

摘要： The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CR3R4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R3 and R4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is O, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.